Current Research | Kaleidoscope Clinica

Current Trials

ITI 421

Main Inclusion Criteria

1. Able to provide consent as follows:

The patient’s legally authorized representative (LAR) (eg, parent or legal guardian) must provide written, informed consent
The patient must provide written assent

2. Male or female patients 10 to 17 years of age

3. Have a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) primary diagnosis of bipolar I or II disorder with a current MDE without psychosis as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL)

4. Subject has a lifetime history of at least one manic or hypomanic episode. A reliable informant (eg, family member or caregiver) or medical records must be able to confirm this history

5. Subject's current major depressive episode is ≥ 4 weeks and less than 12 months in duration

Treatment of Major Depressive Episodes associated with Bipolar I/II Disorder in pediatric patients 10 to 17 years old

Main Exclusion Criteria

Has a primary psychiatric diagnosis other than bipolar I or bipolar II disorder. Exceptions include:
- ADHD. If a subject is taking medications for ADHD, they must have been on a stable treatment regimen of these medication(s) for 30 days prior to screening and the treatment regimen is expected to remain stable throughout the study. This must be confirmed by the investigator and noted in the source records.
- Mild intellectual disability as per investigator discretion and DSM-5 criteria; moderate, severe, and profound intellectual disability are excluded.
Patient has been hospitalized for a bipolar manic episode within the 30 days prior to randomization

CLICK THERAPUTICS

Study Protocol

Inclusion Criteria:

Adult or late adolescent, 18 years of age or older at the time of informed consent.
Fluent in written and spoken English.
Has a primary diagnosis of schizophrenia for at least 6 months prior to the Screening Visit.
Is in the stable phase of illness.
Has outpatient treatment status at the time of screening, with no inpatient treatment for schizophrenia within 12 weeks prior to screening.
Is on a stable dose of antipsychotic medication(s) for at least 12 weeks prior to randomization (Day 1), with dose adjustments permitted during the study as outlined within the respective package inserts of their current medication(s) as determined by the investigator.

Digital Therapeutic (CT-155) as an Adjunct to Antipsychotic Therapy in Adults (18+) with Negative Symptoms of Schizophrenia

Exclusion Criteria

Is currently treated with more than two antipsychotic medications (including more than two dosage forms).
Is currently receiving or has received psychotherapy, defined as individual or group-based structured treatment (e.g., Cognitive Behavioral Therapy, Social Skills Training, or Vocational/Occupational Therapy) within 3 months (13 weeks) prior to screening per investigator assessment.
Meets DSM-5, for diagnoses not under investigation that will impact their compliance to the protocol, including schizophreniform, schizoaffective, or psychosis non-specific disorders (posttraumatic stress disorder [PTSD], bipolar disorder, major depressive disorder, or developmental disorders.
Meets criteria per DSM-5 for a current episode of depression, mania, or hypomania.
Currently needs or will likely require prohibited concomitant medications and/or therapy during the trial, as determined by the investigator.

ACADIA

Study Protocol

A Multicenter, Randomized, Double-blind, Placebo-controlled, Independently Enrolling Two-Part Study for Both Dose-Finding and Confirmation of the Efficacy and Safety of ACP-204 in Adults with Alzheimer’s Disease Psychosis

Indication: Treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP)

Primary objectives are to evaluate efficacy and dose response of ACP-204 60 mg and ACP-204 30 mg compared with placebo in subjects with ADP as measured by the Scale for the Assessment of Positive Symptoms–Hallucinations and Delusions subscales (SAPS-H+D) total score and to evaluate the efficacy of either ACP-204 60 mg or ACP-204 30 mg compared with placebo in subjects with ADP as measured by SAPS-H+D total score.

Inclusion Criteria:

Is a male or female ≥55 and ≤95 years of age living in the community or in an institutionalized setting
Meets clinical criteria for possible or probable Alzheimer’s disease (AD) based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria
Meets the revised criteria for psychosis in major or mild neurocognitive disorder established by the International Psychogeriatrics Association
Has had psychotic symptoms for at least 2 months prior to Screening visit
Has a designated study partner/caregiver (e.g., family member, social worker, case worker or nurse)
Has a prior magnetic resonance imaging (MRI) or computed tomography (CT) scan of the brain (completed within past 3 years from Screening start) taken during or subsequent to the onset of dementia that is consistent with the diagnosis of AD in the Investigator’s judgement. If not available, a non-contrast brain MRI or non-contrast head CT must be done during Screening.
If the subject is taking a cholinesterase inhibitor, memantine, or both:
- The dose of the medication(s) must be stable for at least 12 weeks prior to Visit 2 (Baseline) and there must be no current plan to change the dose during the course of this study; OR
- if the medication(s) was discontinued, the discontinuation must have occurred no fewer than 2 weeks prior to Visit 2 (Baseline).
If the subject is taking an antipsychotic medication at the time of Screening, the antipsychotic must be completely discontinued by 3 days prior to Visit 2 (Baseline)
Must be fully vaccinated against coronavirus disease 2019 (COVID-19) per local standards at least 1 week before the Screening visit; must have a negative COVID-19 diagnostic polymerase chain reaction (PCR) test at Screening; must not be planning to receive a COVID-19 vaccine during the study or within 30 days of the last dose of study drug
If the subject is a female, she must be of nonchildbearing potential, defined as either surgically sterilized (bilateral tubal occlusion) or at least 1 year postmenopausal; OR she must be abstinent for at least 1 month prior to Visit 2 (Baseline), during the study, and 1 month following completion of the study
If the subject is male, he must use a condom (even if vasectomized) from the time of Screening until 90 days after the last dose of study drug. The male subject's female partner must use either an IUD or a barrier method (e.g., condom, diaphragm) plus spermicide; OR the male subject must have a female partner of nonchildbearing potential.

Treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) for adults ≥55 and ≤95

Exclusion Criteria:

Is in hospice, is receiving end-of-life palliative care, or has become bedridden
Requires skilled nursing care (procedures that can only be administered by a registered nurse or doctor, such as but not limited to, intravenous administration of medication, procedures related to insertion or care of suprapubic catheters, and nasopharyngeal/tracheostomy aspiration)
Female who is pregnant or breastfeeding
Has psychotic symptoms that are primarily attributable to delirium, substance abuse, or a medical or psychiatric condition (e.g., schizophrenia, bipolar disorder, delusional disorder) other than dementia
Has had a major depressive episode within 3 months of Screening, according to the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) criteria
Has a GCAS score of 3 or 4 based on Investigator’s assessment of behavior within the 3 months prior to Visit 1 (Screening) or since last visit at Visit 2 (Baseline)
Has evidence of a non-neurologic medical comorbidity or medication use that could substantially impair cognition
Has a history of ischemic or hemorrhagic stroke within the last 12 months with evidence of residual motor or sensory impairment
Has a known history of cerebral amyloid angiopathy, epilepsy, central nervous system (CNS) neoplasm, or unexplained syncope
Has atrial fibrillation unless adequately anticoagulated
Has symptomatic orthostatic hypotension including symptoms such as postural dizziness or pre-syncope, as measured by UKU orthostatic dizziness severity greater than zero, or history of falls associated with orthostatic hypotension, at Screening or Baseline
Has any of the following:
- greater than New York Heart Association Class II congestive heart failure
- grade II or greater angina pectoris (by Canadian Cardiovascular Society Angina Grading Scale)
- sustained ventricular tachycardia
- ventricular fibrillation
- torsade de pointes
- syncope due to an arrhythmia
- an implantable cardiac defibrillator
Had a myocardial infarction within the 6 months prior to Visit 1 (Screening)
Has a known personal or family history or symptoms of long QT syndrome
Has a heart rate <50 beats per minute, as measured by vital signs. If bradycardia is secondary to iatrogenic or treatable causes and these causes are addressed, a heart rate assessment can be repeated during the Screening Period.
Has a significant unstable medical condition that could interfere with subject’s ability to complete the study or comply with study procedures
Known history of infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus (HIV). Subjects with a history of hepatitis B are eligible if there is documentation of a negative test for hepatitis B surface antigen and a positive test for antibodies to the hepatitis B virus surface antigen. Subjects with a history of hepatitis C are eligible if there is documentation of a negative hepatitis C virus RNA test.
Has a clinically significant CNS abnormality that is most likely contributing to the dementia or findings on MRI or CT including:
- intracranial mass lesion (including but not limited to meningioma [>1 cm3 with evidence of peritumoral edema] or glioma)
- vascular malformation
- intracranial aneurysm >4 points by PHASES score
- evidence of >4 hemosiderin deposits (definite microhemorrhage or superficial siderosis)
Has a BMI <18.5 kg/m2 or known unintentional weight loss ≥7% of body weight over past 6 months
Has major surgery planned between Screening and the end of the Safety Follow-up Period
Has a significant sensitivity or allergic reaction to ACP-204 or its excipients
Has a history of non-response to pimavanserin treatment

CTx-1301-004

Study Protocol

Study Title: A Phase 3, Dose-optimized, Randomized, Double-blind, Placebo-Controlled, Parallel Efficacy and Safety Laboratory Classroom Study in Children (6 - 12) with Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (d-MPH)

Clinical Trial: Phase 3

Investigational Product/dosage: CTx-1301, a novel, oral dose of trimodal, extended-release dexmethylphenidate tablet (d-MPH)

Sponsor: Cingulate Therapeutics Inc.

Inclusion Criteria

Patient’s LAR must provide written informed consent; and patient to provide written assent
Male or female subjects between 6 and 12 years of age at the time of consent
Must have a body weight between the 5th and 95th percentile (≥5th percentile and ≤95th percentile) for age and sex
Currently unsatisfied with his/her current pharmacological therapy for treatment of ADHD or not currently receiving pharmacological therapy for ADHD.
Females of childbearing potential must have negative pregnancy test result(s) based on serum b-human chorionic gonadotropin test at Screening
Patient must be in general good health
Patient’s intellectual function is at an age-appropriate level in the opinion of the physician (Principal Investigator)
Must meet Diagnostic and Statistical Manual of Mental Disorders (DSM5) criteria for the primary diagnosis of ADHD
9. Participant must score 28 or higher on the ADHD-RS-5 scale at the screening visit (Visit 1) and Baseline visit (Visit 2)
Patient must be able and willing to wash out of stimulant ADHD medications as indicated per protocol
Patient must have a score of 4 (moderately ill) or higher on the clinician-administrated (CGI-S) scale at Screening (Visit 1)
Patient must be able to swallow the CTx-1301 tablet

Classroom Study in Children (6 - 12) with Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (d-MPH)

Exclusion Criteria:

Pregnant or breastfeeding at any time during the study or for 30 days following the completion of the study
Meets DSM-5 diagnosis for other psychiatric conditions other than the condition under investigation or any diagnosis/significant medical history at the discretion of the physician (Investigator)
Evidence of any chronic disease of the central nervous system (CNS) such as tumors, inflammation, seizure disorder (excluding febrile seizures), vascular disorder, potential CNS-related disorders that might occur in childhood, or history of persistent neurological symptoms related to a serious head injury
Any clinically significant and/or unstable/uncontrolled medical abnormality, chronic medical condition, persistent neurological symptoms, history of cardiovascular abnormality, abnormalities of respiratory, hepatic, gastrointestinal, renal, or any disorder or history of a condition that would impact or interfere with drug absorption, distribution, metabolism, or excretion during the study or may interfere with the participants ability to participate in the study
Family history of early cardiovascular disease or sudden death
Any history of attempted suicide, clinically significant suicidal ideation based on the C-SSRS assessment or answers “yes” to “Suicidal Ideation” item 4 or 5 of any lifetime history on the C-SSRS Children’s Lifetime/Recent assessment at screening
Has a known sleep disorder or history of primary sleep disorder (e.g., sleep apnea, narcolepsy etc.)
Blood pressure < 90th percentile for their age, sex, and height (a single read is sufficient)
Patient is considered treatment refractory or non-compliant by the physician (Investigator) or is intolerant to stimulant ADHD medication
Any use of anticonvulsants currently or within the past 2 years
Any suicidal ideation or behavior, as assessed by the C-SSRS
Uncontrolled thyroid disorder indicated by thyroid stimulating hormone (TSH)
Patient has first-degree relatives (biological parent or sibling) with a history of schizophrenia, schizoaffective disorder, bipolar I disorder, or bipolar II disorder.
Has history of substance abuse or shows evidence of substance or has a positive urine drug screen at Screening visit and/or Baseline visit
Previous treatment experience or exposure to CTx-1301
Any history of allergic reaction or sensitivity to methylphenidate, or dexmethylphenidate, or any other substance contained in CTx-1301 or the placebo drug.
Any prior participation in a classroom trial within 6 months prior to the start of Screening or has participated in any other clinical study with an investigational drug/product within 30 days prior to Screening or is currently participating in another clinical study.
Patient/family anticipated a move outside the geographic range of the investigative site during the duration of the study period or plans on travel that would not allow compliance to the protocol during the study period
Subjects that are siblings are not allowed to be in the same cohort

CT-155-R-001

Study Protocol

Study Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Controlled, 16-week Study to Evaluate the Efficacy and Safety of a Digital Therapeutic (CT-155) as an Adjunct to Standard-of-Care Antipsychotic Therapy in Adult and Late Adolescent Participants with Experiential Negative Symptoms of Schizophrenia

Clinical Trial: Pivotal

Trial Product/dosage: Digital Interactive App

Sponsor: Click Therapeutics, Inc., and Boehringer Ingelheim GmhB

Inclusion Criteria

Participant must provide written informed consent prior to (or at the time of) enrollment
Must be Age 18 years of age or older
Fluent in both written and spoken English with confirmed ability to read and understand
Has primary diagnosis of schizophrenia for at least 6 months prior to Screening Visit
Must be in the stable phase of illness, as assessed by the physician (investigator)
Has outpatient treatment status at the time of screening, with no inpatient
treatment for schizophrenia within 12 weeks prior to screening
Must be on a stable dose of antipsychotic medication(s) for at least 12 weeks prior to Day 1 (randomization)
Has an average score of ≥2 (moderate to severe) in at least two of the three CAINS-MAP domains (Social, Work or Recreational) at the Screening Visit and at baseline (Day 1)
Be the sole user of an iPhone with an iPhone operating system (iOS) 14 or greater, or a smartphone with an Android operating system (OS) 10 or greater, and is willing to download and use the specified Study App per protocol
Be willing and able to receive SMS text messages and push messages on their smartphone
Own an email address and has regular access to the email address
Has regular access to the Internet via cellular data plan and/or wi-fi
Has same residential address (stable housing) for at least 12 weeks prior to screening, with no anticipated housing changes during the duration of the study
Understanding of and interest in the use of the Study App during the screening period and the Baseline Visit (Day 1)

Treatment of adults and late adolescents with negative symptoms of Schizophrenia

Exclusion Criteria:

Currently treated with more than two antipsychotic medications (including more than two dosage forms)
Has a positive symptom item score of >4 (moderate) on P1-Delusions, P2-Disorganization, P3-Hallucinations, P6-Suspiciousness; or a positive symptom item score of >5 (moderate-severe) on items P4-Excitement, P5-Grandiosity; or a general psychopathology item score of >5 (moderate-severe) on items G1 Somatic concern, G3-Guilt feelings, G9-Unusual thought content, G10-Disorientation at the Screening or Baseline Visit on the PANSS, thus indicating prominent positive symptoms
Currently receiving or has received psychotherapy, defined as individual or group-based structured treatment (e.g., Cognitive Behavioral Therapy, Social Skills Training, or Vocational/ Occupational Therapy) within 6 months (26 weeks) prior to screening per Investigator assessment
Meets DSM-5 diagnosis for other psychotic conditions not under investigation that will impact their compliance to the protocol, including schizophreniform, schizoaffective, or psychosis non-specific disorders (posttraumatic stress disorder [PTSD], bipolar disorder, major depressive disorder, or developmental disorders.
Meets criteria per DSM-5 for a current episode of depression, mania, or hypomania
Has a current diagnosis of substance or alcohol use disorder (excluding caffeine and nicotine), as defined in DSM-5, within 6 months (26 weeks) of the Screening Visit
Has a positive urine drug screen at screening or prior to randomization at the Baseline Visit for amphetamines (including MDMA/ecstasy), phencyclidine (PCP), cocaine, opiates, benzodiazepines, or barbiturates.
Has participated in a CT-155 clinical study (CT-155-C-001, CT-155-C-002, CT-155-C-003, CT-155-D-001, CT-155-D-002, CT-155-D-003, or CT-156-C-001); or has participated in other CT-155 user research study (CT-155-P-00x, CT-155-A-001)
Has participated in another clinical study (interventional or observational) in the last 6 months (26 weeks
Currently needs or will likely require prohibited concomitant medications and/or therapy during the trial, as determined by the investigator.
Has suicidal ideation or behavior, as assessed by the C-SSRS:
12. Participants who, in the opinion of the investigator, present a serious

ITI-007-421

Study Protocol

Study Title: ITI-007-421 is a Phase 3, global, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of Lumateperone as treatment for pediatric patients experiencing MDEs associated with bipolar disorder (aged 10-17 years).

Clinical Trial: Phase 3

Trial Product/dosage: Oral Lumateperone (CAPLYTA®) 42mg, once per day

Sponsor: Intra-Cellular Therapies Inc

Inclusion Criteria

Patient’s LAR must provide written informed consent; and patient to provide written assent
Male or female patient 10-17 years of age
Meet DSM-5-TR primary diagnosis of bipolar I or bipolar II disorder with a current MDE without psychosis as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL)
Subject has a lifetime history of at least one manic or hypomanic episode.
Subject's current major depressive episode is ≥ 4 weeks and less than 12 months in duration
CDRS-R score ≥ 45 at Screening (Visit 1) and Baseline (Visit 2)
YMRS score ≤ 15 (with YMRS Item 1 [elevated mood] score ≤ 2) at screening and Baseline
Current outpatient and or anticipated to maintain outpatient for the duration of the study
Female patients of childbearing potential must have negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2)
Body mass index (BMI) greater than the 5th percentile at Screening
Ability to swallow capsules
Ability to follow study instructions and likely to complete required visit

Lumateperone for pediatric patients experiencing MDEs associated with Bipolar Disorder (aged 10-17 years)

Exclusion Criteria:

Has a confirmed primary diagnosis of psychiatric disorder other than schizophrenia or bipolar I or II disorder
Has been hospitalized for a bipolar manic episode within the 30 days prior to randomization;
Demonstrates a ≥ 25% decrease (improvement) in the CDRS-R adjusted total score between Screening and Baseline visits, or the CDRS-R is below 45 at Baseline (Visit 2)
Patient has a significant risk for suicidal behavior or ideation during his/her participation in the study (in the opinion of the physician opinion of the physician (Investigator)
Electroconvulsive therapy (ECT), vagal nerve stimulation, repetitive trans-cranial magnetic stimulation or any other neuromodulation therapies for any CNS and psychiatry indications within the 6 months prior to Screening
Use of monoamine oxidase inhibitors within 14 days prior to Baseline (Visit 2);
Current treatment with clozapine;
Patient has a positive test for alcohol or drugs of abuse
Patient has received a depot/long-acting injectable antipsychotic medication within 2 treatment cycles prior to dosing with study drug;
Patient has had exposure to any investigational product within 3 months of Baseline (Visit 2) or participated in the past 3 years in > 2 clinical studies of an investigational product with a central nervous system indication.
History of human immunodeficiency (HIV) infection
History of seizures, with the exception of febrile seizures

ITI-007-321

Study Protocol

Lumateperone in the Treatment of Pediatric Patients with Schizophrenia (aged 13-17 years) or Bipolar Disorder (aged 10-17 years)

Kaleidoscope Clinical Research is poised to explore a wide range of medical disorders, including but not limited to:

Mental Health & Psychiatry: Headed by a principal investigator specializing in psychiatry, our research initiatives focus on advancing mental health understanding and treatment modalities. From innovative therapies to the exploration of neurobiological mechanisms underlying mental illnesses, our efforts aim to redefine approaches to mental health care.

Cardiovascular Diseases: Led by a sub-principal investigator specializing in cardiology, research initiatives aim to improve prevention, management, and treatment strategies for heart-related conditions.

Neurological Disorders: With a focus on neurology, Kaleidoscope aims to advance the understanding and treatment options for conditions such as strokes, migraines, and neurodegenerative diseases.

Infectious Diseases: Building on the expertise of a sub-principal investigator in infectious diseases, the center actively contributes to research on emerging infections, antimicrobial therapies, and vaccination strategies.

Internal Medicine: Research in this area, guided by a sub-principal investigator in internal medicine, explores a wide spectrum of general health concerns, ensuring a comprehensive approach to healthcare research.

Research Areas Expansion

Team Experience

Our team boasts a rich tapestry of research experience, underscored by a collective dedication to advancing scientific frontiers. With decades of combined expertise spanning diverse disciplines, our researchers, clinicians, and specialists have pioneered groundbreaking studies that have shaped the landscape of medical research.

Dr. Napoleon Higgins Jr.

RESEARCH EXPERIENCE

2022 - 2023

2021

2017 - 2021

2012 - 2021

1995

1993

Principal Investigator, ADHD, Akili, Adult Trial

Principal Investigator, ADHD, Akili, Adolescent Trial

Principal Investigator, Otsuka, Abilify MyCite Pediatric Usability Study

Principal Investigator, MDD, Lundbeck NA Ltd & ICON Clinical Research Services

Principal Investigator, MDD, Anxiety, Sertraline Pediatric Registry for the Evaluation and Safety

Research Assistant. Fred Ernst, Ph.D., Meharry Medical College. Assessed the attitudes of Tennessee residents about needle exchange programs.

Research Assistant. Cleantis Braithewaite, Ph.D., Prairie View A&M University. Tested the reactivity of protein antigens to Corynebacterium pseudotuberculosis in goats.

PHARMACEUTICAL AND INDUSTRY RELATED ACTIVITIES

2022 - present

2021 - present

2019 - present

2016 - 2021

2013 - present

2012 - 2014

2012

2011 - 2013

2010 - 2016

2010 - present

2010 - 2011

2010 - 2013

2007 - 2010

2007 - 2011

2006 - 2012

2006 - present

2005 - 2018

2004 - 2010

2002 - 2015

2000 - 2003

Neurocrine Biosciences, Speakers Bureau

Supernus Pharmaceuticals, Consultant, Speakers Bureau

Noven Pharmaceuticals, Consultant, Speaker

Sage Pharmaceuticals, Consultant, Speaker

Assurex Health, Genesight, Speakers Bureau

Lundbeck Pharmaceuticals, Consultant, Speakers Bureau

Forest Pharmaceuticals

NMA, Training, Minority Principal Investigators in Clinical Research

Shionogi Pharmaceuticals, Speakers Bureau

Sunovion Pharmaceuticals, Speakers Bureau

Otsuka Pharmaceuticals, Consult, Speakers Bureau

Schering-Plough/Merck, Speakers Bureau

BMS, Speakers Bureau

Eli Lilly, Consultant, Speakers Bureau

GSK, Consultant, Speakers Bureau

Novartis, Speakers Bureau

Janssen, Speakers Bureau, Consultant

Shire, Speakers Bureau, Consultant

McNeil, Consultant, Speakers Bureau

AstraZeneca, Speakers Bureau

Pfizer, Speaker

Patient-Centric Continuum

The expansion into diverse medical disciplines retains the patient-centric approach that is central to Kaleidoscope Clinical Research. The commitment to inclusivity, ethical practices, and patient well-being remains unwavering across all research areas, fostering a continuum of compassionate care.

Visionary, Diverse, Inclusive Research

Kaleidoscope Clinical Research, under the visionary leadership of Dr. Napoleon B. Higgins, Jr., MD, transcends the boundaries of mental health research to embrace a holistic healthcare approach. With a diverse team of sub-principal investigators and a commitment to demographically representative research, Kaleidoscope is positioned to contribute significantly to medical advancements that address the unique healthcare needs of the community it serves. As the center expands its research horizons, it invites participants and collaborators to join in shaping a future where healthcare is not only cutting-edge but also deeply rooted in diversity and inclusivity.